- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Shilpa Pharma Lifesciences Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its active pharmaceutical ingredient (API), Nifedipine. This recognition highlights the company's adherence to stringent global quality standards in developing and manufacturing its products. Nifedipine is widely used for treating hypertension and angina by relaxing blood vessels and improving blood flow. This certification not only reinforces Shilpa's commitment to high-quality production but also opens up new market opportunities, potentially enhancing the company’s revenue stream and market presence. Investors should view this development as a positive indicator of Shilpa’s growth potential and strategic positioning in the pharmaceutical sector.